The Incretin Effect
Eli Lilly and Company |
Thursday
Coming soon… 22.09.2022 08:15 – 08:25 VIRTUAL ONLY: Cori Hall
Coming soon… 22.09.2022 08:15 – 08:25 VIRTUAL ONLY: Cori Hall
18:30 – 18:50 CGM in ADA / EASD Consensus report. Use of Eversense in diabetes treatment. Tomasz Klupa (POL) 18:50 – 19:10 Eversense CGM System
Chair: Eric Renard (FRA) 18:30 – 19:00 Freedom of Choice & Diabetes Management with the Omnipod DASH® System Emma Wilmot (UK) 19:00 – 19:30 Omnipod®
Chair: Per-Henrik Groop (FIN) 18:30 – 18:35 Welcome & Introduction Per-Henrik Groop (FIN) 18:35 – 18:45 Removing barriers to the treatment of CKD Jennifer Green
Chair: Péter Kempler (HUN) 18:30 – 18:35 Introduction & Welcoming by EVA Pharma Riad Armanious (EGY) 18:35 – 18:50 Diabetic Neuroapthy, A therapeutic approach from
Chair: John Buse (USA) 18:30 – 18:35 Welcome, pre-symposium test & chair’s opening remarks John Buse (USA) 18:35 – 18:45 True or False quiz: GLP-1 RA general
Chair: Samy Hadjadj (FRA) 18:30 – 18:35 Welcome and introductions Samy Hadjadj (FRA) 18:35 – 19:00 Optimising treatment of CKD associated with T2D: Time for
